Patent settlements between originator and generic firms in the pharmaceutical industry are a controversial topic, both in EU competition policy and U.S. antitrust law. The main concern is that patent settlements, which involve large payments from the originator to generic firms (reverse...

In this work, I study the determinants of (implicit) trademark value. My approach is based on the idea that more valuable marks are likely to remain under legal protection, as long as the benefits of this protection exceed its costs, than less valuable marks. In order to test this idea, I...

The study is an exploratory study on the state of exports within the Ghanaian pharmaceutical manufacturing industry. Data was obtained from interviews of key managers involved in strategy formulation of 5 exporting pharmaceutical manufacturing companies in Ghana. The study revealed that out of...

In the pharmaceuticals sector there is an inherent tension between intellectual property rights and antitrust. This paper examines this tension over the past 10 years since modernisation of EU competition law. It looks at three types of problems: (i) restrictions on parallel imports; (ii) abuse...

The business organizations have a propensity to show their performances by achieving greater sales performances in the field. In this, the role of sales force of high importance and the organizations are adopting dynamic marketing and selling strategies and implementing those strategies to their...

We present a Hotelling model of price and advertising competition between prescription drugs that differ in quality/side effects. Promotional effort results in the endogenous formation of two consumer groups: brand loyal and non-brand loyal ones. We show that advertising intensities are...

Drug development is costly so drug makers need accurate estimates of sales potential. However, sales forecasts are often unreliable. Our study is unique in combining a large sample of drug classes with data on entry order and promotional spending to estimate peak market share while controlling...

The global pharmaceutical industry is in an era of greater uncertainty because of looming patent expiries of established drugs having a direct impact on their sales and profitability. Further discovering new drugs in-house is a risky, time consuming and expensive proposition. This has forced...

This paper estimates three duration models, one for each of the three clinical phases of drug development using publicly available data. Specifically, we estimate three discrete time mixed proportional hazard models, with some parameter constraints across models. We present the estimated...

When the Indian economy shifted from a process patent regime to a product patent regime in 2005, there was a thought as to whether Indian pharma companies would be able to weather the change in the regime. However, they have indeed succeeded in this transition and have grown in size. The world...